A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

This study has been terminated.
(Voluntary halt of further dosing due to an FDA Clinical Hold issued in relation to Dynavax study DV2-HBV-10)
Sponsor:
Information provided by:
Dynavax Technologies Corporation
ClinicalTrials.gov Identifier:
NCT00498212
First received: July 5, 2007
Last updated: October 6, 2008
Last verified: October 2008

July 5, 2007
October 6, 2008
July 2007
August 2008   (final data collection date for primary outcome measure)
Occurrence of adverse events and local and systemic reaction rates [ Time Frame: 28 weeks ] [ Designated as safety issue: Yes ]
  • AE rate [ Time Frame: 1 year ]
  • safety laboratory review [ Time Frame: 1 year ]
Complete list of historical versions of study NCT00498212 on ClinicalTrials.gov Archive Site
Portion of subjects who have a seroprotective immune response (anti-HBsAg ≥ 10 mIU/ml) [ Time Frame: 50 weeks ] [ Designated as safety issue: No ]
  • Geometric Mean Concentration (GMC) of anti-hepatitis B antibodies [ Time Frame: 1 year ]
  • proportion of subjects with immune response [ Time Frame: 1 year ]
Not Provided
Not Provided
 
A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease
A Phase 2, Single-Blind, Randomized Study of Safety and Immunogenicity Following Vaccination With Single or Double Doses of HEPLISAV™ in Adults With End-Stage Renal Disease

The purpose of this study is to find out if a new investigational hepatitis B virus (HBV) vaccine, HEPLISAV™, is safe and effective for end-stage renal disease (ESRD) patients. Two dose levels will be studied: a single dose and a double dose. We expect both dose levels to safely immunize patients against HBV. The study will determine which dose does this best.

Infection with hepatitis B virus (HBV) is a major global health problem. Worldwide, it is estimated that 2 billion people have been infected previously and 350 million are chronically infected. While acute HBV infection is associated with significant illness, the risk of chronic infection is of great importance since 5-10% of infected adults will not clear the infection after the initial phase of the illness. About 25% of people who do not initially clear the infection will later develop chronic active hepatitis.

This study will evaluate the safety and immunogenicity of HEPLISAV™ when administered to adults who have end-stage renal disease (glomerular filtration rate [GFR] ≤ 45 mL/min). Once subjects have been consented, screened, and randomized to treatment, subjects will receive a total of three injections over a 24-week period, with follow-up visits at 28 and 50 weeks. Subjects will receive 1 of the following 2 regimens:

  • HEPLISAV™ single dose at Day 0, 4 weeks (1 month) and 24 weeks (6 months)
  • HEPLISAV™ double dose at Day 0, 4 weeks (1 month) and 24 weeks (6 months)

Safety and tolerability will be evaluated by occurrence of adverse events, periodic laboratory tests, vital signs, and local and systemic reactogenicity.

Immunogenicity will be evaluated by the proportion of subjects exhibiting a seroprotective immune response (anti-hepatitis B surface antigen antibodies [anti-HBsAg] ≥ 10 mIU/mL) at Weeks 4, 12, 24, 28 and 50.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Hepatitis B
Biological: 1018 ISS immunostimulatory oligonucleotide with recombinant HB surface antigen
IM (in the muscle) injection at Day 0, Week 4 and Week 24
Other Name: HEPLISAV™
  • Experimental: 1
    Single dose (3000 µg 1018 ISS + 20 µg rHBsAg)
    Intervention: Biological: 1018 ISS immunostimulatory oligonucleotide with recombinant HB surface antigen
  • Experimental: 2
    Double dose (6000 µg 1018 ISS + 40 µg rHBsAg)
    Intervention: Biological: 1018 ISS immunostimulatory oligonucleotide with recombinant HB surface antigen
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
41
October 2008
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Willing and able to give written informed consent
  • Have a glomerular filtration rate (GFR) ≤ 45 mL/min
  • Have an expectation of going on hemodialysis or are already on hemodialysis
  • Is serum negative for hepatitis B virus (HBV) antibodies, hepatitis C virus (HCV), and human immunodeficiency virus (HIV)
  • Have repeated resting blood pressure measurements ≤ 165/105 mmHg
  • Women of childbearing potential must be consistently using a highly effective method of birth control

Exclusion Criteria:

  • Women who are pregnant, breastfeeding or planning a pregnancy
  • Any previous HBV infection
  • Previous vaccination (1 or more doses) with any HBV vaccine
  • Any previous autoimmune diseases
  • Have a diagnosis of chronic renal failure due to autoimmune disease
  • Are at high risk for recent exposure to HBV, HCV or HIV
  • Received any antibodies within 3 months prior to study entry
  • Ever received an injection with DNA plasmids or oligonucleotides
  • Received any vaccines within 4 weeks prior to study entry
  • Received any other investigational medicinal agent within 4 weeks prior to study entry
Both
40 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00498212
DV2-HBV-11
Yes
Eduardo Martins, MD, DPhil / Vice President, Clinical Development, Dynavax Technologies Corporation
Dynavax Technologies Corporation
Not Provided
Study Director: Eduardo Martins, MD, D Phil Dynavax Technologies Corporation
Dynavax Technologies Corporation
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP